{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Moderate+and+Severe+Plaque+Psoriasis",
    "query": {
      "condition": "Moderate and Severe Plaque Psoriasis"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 230,
    "total_pages": 23,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Moderate+and+Severe+Plaque+Psoriasis&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T14:55:24.898Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00292396",
      "title": "Efficacy and Safety of ABT-874 in Subjects With Moderate to Severe Chronic Plaque Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "Anti IL-12 monoclonal antibody/ABT-874",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie (prior sponsor, Abbott)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 180,
      "start_date": "2005-11",
      "completion_date": "2008-04",
      "has_results": false,
      "last_update_posted_date": "2013-01-18",
      "last_synced_at": "2026-07-23T14:55:24.898Z",
      "location_count": 16,
      "location_summary": "San Diego, California • Alpharetta, Georgia • Skokie, Illinois + 13 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Alpharetta",
          "state": "Georgia"
        },
        {
          "city": "Skokie",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00292396"
    },
    {
      "nct_id": "NCT00585650",
      "title": "Study of Tumor Necrosis Factor Receptor Fusion Protein Etanercept (Enbrel) in Psoriasis of the Hands and/or Feet",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "Etanercept",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo injections",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "University of California, Irvine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 20,
      "start_date": "2007-05",
      "completion_date": "2008-05",
      "has_results": true,
      "last_update_posted_date": "2023-08-18",
      "last_synced_at": "2026-07-23T14:55:24.898Z",
      "location_count": 3,
      "location_summary": "Irvine, California • Winston-Salem, North Carolina • Seattle, Washington",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00585650"
    },
    {
      "nct_id": "NCT03668613",
      "title": "Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Moderate to Severe Chronic Plaque-type Psoriasis"
      ],
      "interventions": [
        {
          "name": "secukinumab low dose",
          "type": "DRUG"
        },
        {
          "name": "secukinumab high dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 84,
      "start_date": "2018-08-29",
      "completion_date": "2023-09-12",
      "has_results": true,
      "last_update_posted_date": "2025-05-16",
      "last_synced_at": "2026-07-23T14:55:24.898Z",
      "location_count": 4,
      "location_summary": "Fountain Valley, California • Jacksonville, Florida • Lebanon, New Hampshire + 1 more",
      "locations": [
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03668613"
    },
    {
      "nct_id": "NCT02660580",
      "title": "MSB11022 in Moderate to Severe Chronic Plaque Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Psoriasis",
        "Plaque Type Psoriasis",
        "Moderate to Severe Plaque Psoriasis"
      ],
      "interventions": [
        {
          "name": "MSB11022",
          "type": "DRUG"
        },
        {
          "name": "Humira®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fresenius Kabi SwissBioSim GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 443,
      "start_date": "2016-02-16",
      "completion_date": "2017-12-18",
      "has_results": true,
      "last_update_posted_date": "2023-12-27",
      "last_synced_at": "2026-07-23T14:55:24.898Z",
      "location_count": 6,
      "location_summary": "San Luis Obispo, California • Coral Gables, Florida • West Palm Beach, Florida + 2 more",
      "locations": [
        {
          "city": "San Luis Obispo",
          "state": "California"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02660580"
    },
    {
      "nct_id": "NCT04175613",
      "title": "A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "Apremilast",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 160,
      "start_date": "2019-12-20",
      "completion_date": "2025-12-12",
      "has_results": false,
      "last_update_posted_date": "2025-12-22",
      "last_synced_at": "2026-07-23T14:55:24.898Z",
      "location_count": 13,
      "location_summary": "Phoenix, Arizona • Fort Smith, Arkansas • Irvine, California + 10 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Thousand Oaks",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04175613"
    },
    {
      "nct_id": "NCT04607980",
      "title": "A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Plaque Psoriasis"
      ],
      "interventions": [
        {
          "name": "ABP 654",
          "type": "DRUG"
        },
        {
          "name": "Ustekinumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 563,
      "start_date": "2020-11-11",
      "completion_date": "2022-06-03",
      "has_results": true,
      "last_update_posted_date": "2024-12-12",
      "last_synced_at": "2026-07-23T14:55:24.898Z",
      "location_count": 34,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 30 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Luis Obispo",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04607980"
    },
    {
      "nct_id": "NCT04718896",
      "title": "A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Moderate to Severe Plaque Psoriasis"
      ],
      "interventions": [
        {
          "name": "bimekizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UCB Biopharma SRL",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 41,
      "start_date": "2021-04-06",
      "completion_date": "2025-03-12",
      "has_results": true,
      "last_update_posted_date": "2026-05-18",
      "last_synced_at": "2026-07-23T14:55:24.898Z",
      "location_count": 2,
      "location_summary": "Indianapolis, Indiana • Cypress, Texas",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Cypress",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04718896"
    },
    {
      "nct_id": "NCT05272150",
      "title": "Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Plaque Psoriasis",
        "Scalp Psoriasis"
      ],
      "interventions": [
        {
          "name": "Guselkumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 211,
      "start_date": "2022-07-13",
      "completion_date": "2025-05-30",
      "has_results": true,
      "last_update_posted_date": "2026-06-24",
      "last_synced_at": "2026-07-23T14:55:24.898Z",
      "location_count": 79,
      "location_summary": "Birmingham, Alabama • Beverly Hills, California • Encinitas, California + 67 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05272150"
    },
    {
      "nct_id": "NCT01483924",
      "title": "Study to Evaluate Apo805K1 in Subjects With Moderate to Severe Chronic Plaque Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Plaque Psoriasis"
      ],
      "interventions": [
        {
          "name": "Apo805K1",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ApoPharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 60,
      "start_date": "2011-11",
      "completion_date": "2013-10",
      "has_results": true,
      "last_update_posted_date": "2015-02-20",
      "last_synced_at": "2026-07-23T14:55:24.898Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • Dallas, Texas • Houston, Texas + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01483924"
    },
    {
      "nct_id": "NCT02074982",
      "title": "Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Plaque Type Psoriasis"
      ],
      "interventions": [
        {
          "name": "AIN457 300 mg",
          "type": "DRUG"
        },
        {
          "name": "ustekinumab 45/90 mg",
          "type": "DRUG"
        },
        {
          "name": "placebo secukinumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 676,
      "start_date": "2014-02-26",
      "completion_date": "2016-06-29",
      "has_results": true,
      "last_update_posted_date": "2017-07-21",
      "last_synced_at": "2026-07-23T14:55:24.898Z",
      "location_count": 26,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 22 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02074982"
    }
  ]
}